In conclusion, our prospective study applied IHC to measure ERCC1, RRM1, and β-tubulin III expression in biopsies, and assessed the potential benefits of the three molecular biomarker-guided chemotherapy and the adverse effects in the treatment for NSCLC. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.